Vaccibody part of project that has successfully landed EU Horizon 2020 funding

Oslo Cancer Cluster member Vaccibody AS wil take part in SAPHIR, a 4 year collaborative research project that has succesfully raised 78 million NOK from the EU Horizon 2020 program. SAPHIR brings together interdisciplinary expertise from 14 academic institutions, 5 small and medium-sized enterprises  and 2 pharmaceutical companies. The project aims to improve animal production and health through development of improved vaccination strategies. 

Vaccibody is dedicated to the development of novel immunotherapies and vaccines for prevention and treatment of cancer and infectious diseases for human and veterinary purposes. For SAPHIR, Vaccibody will provide vaccines against Porcine Reproductive and Respiratory Syndrome Virus for evaluation in pigs. Upon successful completion of the SAPHIR project, Vaccibody will have increased expertise and network within the veterinary vaccine and administration field.

Tom Pike, Chairman and Acting CEO of Vaccibody, commented: “This is another example of how Vaccibody intends to broaden the use of our platform technology in collaboration with acknowledged partners. We recently attended the kick-off meeting in Paris and we are proud to be a part of this international consortium with expertise within veterinary vaccine development. The support from EU for collaborative initiatives like SAPHIR will allow Vaccibody to expand its experience of the technology within the veterinary field while the company remains fully focused on the clinical development of it’s lead drug candidate, VB10.16 for treatment of HPV16 induced precancer and cancer.”


About Vaccibody AS

Vaccibody is a biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, prophylactic and therapeutic vaccines which target cancer and infectious diseases, for human and veterinary use. Vaccibody’s lead drug candidate VB10.16 is a therapeutic DNA vaccine against HPV16 induced pre-malignancies and malignancies. The company is currently entering it’s first-in-man study that will evaluate the safety and immunogenicity of VB10.16 in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3).